Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Combined PARP and immune checkpoint inhibition has yielded encouraging results in ovarian cancer, but predictive biomarkers are lacking. We performed immunogenomic profiling and highly multiplexed single-cell imaging on tumor samples from patients enrolled in a Phase I/II trial of niraparib and pemb...

Descripción completa

Detalles Bibliográficos
Autores principales: Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., Konstantinopoulos, Panagiotis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081234/
https://www.ncbi.nlm.nih.gov/pubmed/32193378
http://dx.doi.org/10.1038/s41467-020-15315-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081234/
https://www.ncbi.nlm.nih.gov/pubmed/32193378
http://dx.doi.org/10.1038/s41467-020-15315-8

Ejemplares similares